Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VM-PSY-005
- Development stage
- Preclinical
- Lead developer
- VivaMed
- Modality
- Small Molecules
01
Overview
VM-PSY-005 is a preclinical-stage small molecule candidate being developed by VivaMed for the treatment of Opioid Use Disorder (OUD). It is part of the company's psychiatric pipeline (VM-PSY series), which focuses on addressing various substance use disorders. While the specific pharmacological target of VM-PSY-005 has not been publicly identified, the program aims to provide a new therapeutic option for OUD, a condition characterized by a problematic pattern of opioid use leading to significant impairment or distress. The candidate is currently undergoing preclinical evaluation to support future clinical development.
Beyond the preview
Go deeper on VM-PSY-005.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VM-PSY-005.